New industry research reveals that more than one third, 36%, of pharmaceutical manufacturers and contract packagers are not currently preparing for global serialization requirements, despite impending deadlines.
The research, conducted by serialization system provider SEA Vision and life science technology firm Zenith Technologies, highlights an urgent need for companies to turn their attention to meeting the demands of the US Drug Supply Chain Security Act (DSCSA) and the European Falsified Medicines Directive (FMD).
Out of those companies that are not preparing for the new regulations, around half, 51%, say it is because they don’t currently have enough internal resource to devote to serialization, while 15% believe it is too early to begin preparations.
“Our research has confirmed that many companies are under-estimating the enormity of the task at hand. Preparing for serialization is a complex process that is so much more than simply integrating new technology on a packaging line. Instead, it should be a company-wide initiative, involving all corners of an organization and the wider pharmaceutical supply chain,” Carlos Machado, serialization director at SEA Vision US, said.
For 56% of those that have begun their serialization journey, compliance is the only goal of their serialization project at this stage. Just 44% intend to use the process to achieve wider business benefits.
In 2016, SEA Vision and Zenith Technologies formed a global partnership to support pharmaceutical companies with the impending challenge of installing and integrating serialization across drug manufacturing sites.
The collaboration brings together Italian-based SEA Vision’s serialization system along with global Zenith Technologies’ ability to integrate systems and deliver ongoing technical support at a local level.